All In MedTech

Device Trial Radar · NCT03840395

The PhINEST Study - Pharyngeal ICU Novel Electrical Stimulation Therapy

The PhINEST Study - Pharyngeal ICU Novel Electrical Stimulation Therapy: a Prospective, Multi-site, Randomised, Sham-controlled, Single-blind (Outcome Assessor-blinded) Study.

Last checked: Nov 20, 2026Latest source record: May 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

72

Actual

Start

Jun 17, 2019

Primary completion

Aug 1, 2025

Study completion Dec 31, 2025

Sponsor

Lead sponsor
Phagenesis Ltd.Not on our public-company list
Sponsor type
Industry
Collaborators
NAMSA; Cytel Inc.
First posted
Feb 15, 2019

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Triple (care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, multi-site, randomised, sham-controlled, single-blind (outcome assessor-blinded) study designed to assess the effects of Pharyngeal Electrical Stimulation (PES) (using Phagenyx®) for the treatment of oropharyngeal dysphagia after invasive mechanical ventilation (of any duration) by means of naso or oro-tracheal tube in critically ill intensive care unit (ICU) patients.

Conditions

  • Dysphagia

Interventions

  • Pharyngeal Electrical Stimulation (PES)Device

    The Phagenyx® system is a two-part neurostimulation system. It is composed of a durable component called the Base Station and the single-use sterile disposable Catheter. The Base Station acts as the user interface and provides the means to generate, optimize and monitor the delivery of electrical stimulation to the oropharynx. The Phagenyx® devices are CE labelled (2012) and will be used in accordance with their intended use label.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Effectiveness of Phagenyx® treatment in reducing severity of unsafe swallows - Penetration-Aspiration Scale (PAS) ScoresTime frame: Day 2 (~24 to ~60 hours) after the final Phagenyx® treatment
  2. Effectiveness of Phagenyx® treatment in reducing the severity of unsafe swallows - Dysphagia Outcome and Severity Score (DOSS) scoreTime frame: 7±1 days after the final Phagenyx® treatment

Locations

5 sites in 3 countries. Site status is shown where the registry gives one.

  • Medizinische Universität Innsbruck - Medizinische Universität Innsbruck

    Innsbruck, Austria

  • Medizinische Universität Innsbruck - Universitätsklinik für Anästhesie und Intensivmedizin

    Innsbruck, Austria

  • Medizinische Universität Innsbruck - Universitätsklinik für Innere Medizin I

    Innsbruck, Austria

2 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.